{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:06:47Z","timestamp":1792195607927,"version":"4.4.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.mayocp.2017.04.010","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T22:16:51Z","timestamp":1496873811000},"page":"1088-1103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":449,"title":["Crohn Disease: Epidemiology, Diagnosis, and Management"],"prefix":"10.1016","volume":"92","author":[{"given":"Joseph D.","family":"Feuerstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2017.04.010_bib1","first-page":"264","article-title":"Morbid appearances in the intestine of Miss Bankes","volume":"2","author":"Wilks","year":"1859","journal-title":"London Med Times Gazette"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0016-5085(98)70421-4","article-title":"Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival","volume":"114","author":"Loftus","year":"1998","journal-title":"Gastroenterology"},{"issue":"42","key":"10.1016\/j.mayocp.2017.04.010_bib3","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","article-title":"Prevalence of inflammatory bowel disease among adults aged\u2265 18 years\u2014United States, 2015","volume":"65","author":"Dahlhamer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.mayocp.2017.04.010_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.mayocp.2017.04.010_bib5","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1001\/jama.2013.4466","article-title":"Management of active Crohn disease","volume":"309","author":"Cheifetz","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.mayocp.2017.04.010_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/gutjnl-2012-303661","article-title":"Geographical variability and environmental risk factors in inflammatory bowel disease","volume":"62","author":"Ng","year":"2013","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib8","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","article-title":"The microbiome in inflammatory bowel disease: current status and the future ahead","volume":"146","author":"Kostic","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2009.04.001","article-title":"Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis","volume":"137","author":"Gradel","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-156-5-201203060-00007","article-title":"Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study","volume":"156","author":"Ananthakrishnan","year":"2012","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2036.2005.02564.x","article-title":"Risk factors for inflammatory bowel disease in the general population","volume":"22","author":"Garc\u00eda Rodr\u00edguez","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib13","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1542\/peds.2011-3886","article-title":"Antibiotic exposure and IBD development among children: a population-based cohort study","volume":"130","author":"Kronman","year":"2012","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.mayocp.2017.04.010_bib14","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/j.1572-0241.2008.02064.x","article-title":"The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis","volume":"103","author":"Cornish","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1053\/j.gastro.2012.07.096","article-title":"Hormone therapy increases risk of ulcerative colitis but not Crohn's disease","volume":"143","author":"Khalili","year":"2012","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mayocp.2017.04.010_bib16","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4065\/81.11.1462","article-title":"Smoking and inflammatory bowel disease: a meta-analysis","volume":"81","author":"Mahid","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.mayocp.2017.04.010_bib17","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/ajg.2012.196","article-title":"A\u00a0prospective study of cigarette smoking and the risk of inflammatory bowel disease in women","volume":"107","author":"Higuchi","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.04.010_bib18","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1111\/j.1572-0241.2008.02118.x","article-title":"The risk of developing Crohn's disease after an appendectomy: a meta-analysis","volume":"103","author":"Kaplan","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.04.010_bib19","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/j.1572-0241.2007.01411.x","article-title":"Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children","volume":"102","author":"Amre","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00054725-200502000-00009","article-title":"Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan","volume":"11","author":"Sakamoto","year":"2005","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2011.44","article-title":"Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature","volume":"106","author":"Hou","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mayocp.2017.04.010_bib22","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0016-5085(03)00385-8","article-title":"Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics","volume":"124","author":"Halfvarson","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/gut.34.4.517","article-title":"Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews","volume":"34","author":"Yang","year":"1993","journal-title":"Gut"},{"issue":"7023","key":"10.1016\/j.mayocp.2017.04.010_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/bmj.312.7023.95","article-title":"Genetics versus environment in inflammatory bowel disease: results of a British twin study","volume":"312","author":"Thompson","year":"1996","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.mayocp.2017.04.010_bib25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/003655200451207","article-title":"Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study","volume":"35","author":"Orholm","year":"2000","journal-title":"Scand J Gastroenterol"},{"issue":"6837","key":"10.1016\/j.mayocp.2017.04.010_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"issue":"6837","key":"10.1016\/j.mayocp.2017.04.010_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/35079114","article-title":"A\u00a0frameshift mutation in NOD2 associated with susceptibility to Crohn's disease","volume":"411","author":"Ogura","year":"2001","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bpg.2003.12.004","article-title":"Towards an understanding of the role of NOD2\/CARD15 in the pathogenesis of Crohn's disease","volume":"18","author":"Philpott","year":"2004","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MOG.0000000000000188","article-title":"Gene\u2013environment interactions in inflammatory bowel disease pathogenesis","volume":"31","author":"Wang","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"issue":"10014","key":"10.1016\/j.mayocp.2017.04.010_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"Cleynen","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.gastro.2013.05.050","article-title":"Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics","volume":"145","author":"Ventham","year":"2013","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.cgh.2006.03.003","article-title":"The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis\u2013how much is irritable bowel syndrome?","volume":"4","author":"Burgmann","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9853","key":"10.1016\/j.mayocp.2017.04.010_bib33","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory markers in\u00a0IBD: useful, magic, or unnecessary toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.mayocp.2017.04.010_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bpg.2008.12.005","article-title":"Serum sickness, encephalitis and other complications of anti-cytokine therapy","volume":"23","author":"Vermeire","year":"2009","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11894-008-0108-6","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"10","author":"Williams","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","article-title":"Ankylosing spondylitis and bowel disease","volume":"20","author":"Rudwaleit","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11926-000-0045-3","article-title":"Arthritis and inflammatory bowel disease","volume":"2","author":"Wordsworth","year":"2000","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"10.1016\/j.mayocp.2017.04.010_bib40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.clindermatol.2007.10.018","article-title":"Skin manifestations of inflammatory bowel disease","volume":"26","author":"Timani","year":"2008","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.04.010_bib42","first-page":"6","article-title":"Primary sclerosing cholangitis: an update","volume":"1","author":"Feuerstein","year":"2013","journal-title":"OA Hepatol"},{"issue":"9904","key":"10.1016\/j.mayocp.2017.04.010_bib43","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/gut.20.4.269","article-title":"The granuloma in Crohn's disease","volume":"20","author":"Chambers","year":"1979","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/gut.2004.041715","article-title":"Frequency and significance of granulomas in a cohort of incident cases of Crohn's disease","volume":"54","author":"Heresbach","year":"2005","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.mayocp.2017.04.010_bib46","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1038\/ajg.2009.404","article-title":"The utility of capsule endoscopy in patients with suspected Crohn's disease","volume":"104","author":"Tukey","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gut.52.3.390","article-title":"Diagnosing small bowel Crohn's disease with wireless capsule endoscopy","volume":"52","author":"Fireman","year":"2003","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.mayocp.2017.04.010_bib48","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2006.00761.x","article-title":"The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease","volume":"101","author":"Cheifetz","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.dld.2006.01.010","article-title":"Use of the Given\u00ae Patency System for the screening of patients at high risk for capsule retention","volume":"38","author":"Signorelli","year":"2006","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bpg.2014.04.010","article-title":"Diagnostic imaging in Crohn's disease: what is the new gold standard?","volume":"28","author":"Dambha","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib51","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1572-0241.2001.03613.x","article-title":"Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease","volume":"96","author":"Peeters","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.04.010_bib52","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/j.1572-0241.2004.40369.x","article-title":"Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype","volume":"99","author":"Zholudev","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib53","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti\u2013TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib54","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/gutjnl-2011-301397","article-title":"Hospitalisations and surgery in Crohn's disease","volume":"61","author":"Bernstein","year":"2012","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.mayocp.2017.04.010_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016, part 1: Diagnosis and Medical Management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"12","key":"10.1016\/j.mayocp.2017.04.010_bib56","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2006.12.012","article-title":"A\u00a0meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease","volume":"28","author":"Rahimi","year":"2006","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib57","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mayocp.2017.04.010_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000067.pub3","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib59","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease","volume":"145","author":"Pan\u00e9s","year":"2013","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.mayocp.2017.04.010_bib60","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2017.04.010_bib63","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib64","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2036.2008.03753.x","article-title":"Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease","volume":"28","author":"Panaccione","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.04.010_bib66","first-page":"2116","article-title":"Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis","volume":"89","author":"Steinhart","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib67","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ibd.20135","article-title":"5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists","volume":"13","author":"Gearry","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib68","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1017987229718","article-title":"Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systemic review","volume":"47","author":"Gisbert","year":"2002","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib69","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2036.2002.01216.x","article-title":"Review article: monitoring for drug side-effects in inflammatory bowel disease","volume":"16","author":"Cunliffe","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib70","first-page":"328","article-title":"An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin","volume":"91","author":"Prantera","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib71","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/gast.2002.32362","article-title":"The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota","volume":"122","author":"Schwartz","year":"2002","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.mayocp.2017.04.010_bib72","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","article-title":"A\u00a0global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease","volume":"63","author":"Gecse","year":"2014","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib73","first-page":"CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn's disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mayocp.2017.04.010_bib74","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1365-2036.2001.01060.x","article-title":"Review article: the limitations of corticosteroid therapy in Crohn's disease","volume":"15","author":"Rutgeerts","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.mayocp.2017.04.010_bib75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A\u00a0comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib76","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib77","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib78","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ecco-jcc\/jjw055","article-title":"European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease","volume":"10","author":"Rieder","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib79","first-page":"461","article-title":"Corticosteroid-associated complications in elderly Crohn's disease patients","volume":"92","author":"Akerkar","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib80","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.04.010_bib81","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"18","key":"10.1016\/j.mayocp.2017.04.010_bib82","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib83","first-page":"CD006884","article-title":"Methotrexate for maintenance of remission in Crohn's disease","author":"Patel","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mayocp.2017.04.010_bib84","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Chande","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.mayocp.2017.04.010_bib85","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib86","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11894-007-0068-2","article-title":"Optimizing drug therapy in inflammatory bowel disease","volume":"9","author":"Swaminath","year":"2007","journal-title":"Curr Gastroenterol Rep"},{"issue":"9","key":"10.1016\/j.mayocp.2017.04.010_bib87","doi-asserted-by":"crossref","first-page":"716","DOI":"10.7326\/0003-4819-129-9-199811010-00007","article-title":"Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine","volume":"129","author":"Black","year":"1998","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib88","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1053\/j.gastro.2004.09.061","article-title":"Use of laboratory testing to guide 6-mercaptopurine\/azathioprine therapy","volume":"127","author":"Lichtenstein","year":"2004","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mayocp.2017.04.010_bib89","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2362.2010.02346.x","article-title":"Thiopurine metabolism monitoring: implications in inflammatory bowel diseases","volume":"40","author":"Dewit","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"9701","key":"10.1016\/j.mayocp.2017.04.010_bib90","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib91","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2036.2010.04330.x","article-title":"Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease","volume":"32","author":"Smith","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"41","key":"10.1016\/j.mayocp.2017.04.010_bib92","doi-asserted-by":"crossref","first-page":"e1513","DOI":"10.1097\/MD.0000000000001513","article-title":"Safety profile of thiopurines in Crohn disease: analysis of 893 patient-years follow-up in a Southern China cohort","volume":"94","author":"Qiu","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib93","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.crohns.2011.12.003","article-title":"Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy","volume":"6","author":"Gilissen","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1440-1746.2011.06865.x","article-title":"Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study","volume":"27","author":"Setshedi","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"22","key":"10.1016\/j.mayocp.2017.04.010_bib95","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A\u00a0comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib96","first-page":"CD003459","article-title":"Methotrexate for induction of remission in refractory Crohn's disease","author":"McDonald","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib97","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-2007-991026","article-title":"Medical management of Crohn's disease","volume":"20","author":"Feldman","year":"2007","journal-title":"Clin Colon Rectal Surg"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib98","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib99","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archderm.143.5.663-b","article-title":"Methotrexate and risk for lymphoma","volume":"143","author":"Whitmore","year":"2007","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.04.010_bib100","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2014-307126","article-title":"Systematic review: monotherapy with antitumour necrosis factor \u03b1 agents versus combination therapy with an immunosuppressive for IBD","volume":"63","author":"Dulai","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib101","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti\u2013tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.mayocp.2017.04.010_bib102","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib103","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib104","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2017.04.010_bib105","unstructured":"American Gastroenterological Association. Adult Inflammatory Bowel Disease Physician Performance Measures Set. Vol 20132011. http:\/\/www.gastro.org\/practice\/quality-initiatives\/IBD_Measures.pdf. Accessed February 1, 2017."},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib106","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cgh.2016.03.038","article-title":"Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn's disease","volume":"14","author":"Singh","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib107","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A\u00a0test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.04.010_bib108","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib109","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cgh.2010.04.023","article-title":"The appropriateness of concomitant immunomodulators with anti\u2013tumor necrosis factor agents for Crohn's disease: one size does not fit all","volume":"8","author":"Melmed","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib110","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib111","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1097\/MIB.0000000000000279","article-title":"Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease","volume":"21","author":"Feuerstein","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.mayocp.2017.04.010_bib112","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/ajg.2013.294","article-title":"Infectious and malignant complications of TNF inhibitor therapy in IBD","volume":"108","author":"Targownik","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib113","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.gtc.2014.05.009","article-title":"Anti\u2013tumor necrosis factor-\u03b1 monotherapy versus combination therapy with an immunomodulator in IBD","volume":"43","author":"Dulai","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"issue":"1","key":"10.1016\/j.mayocp.2017.04.010_bib114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A\u00a0systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.04.010_bib115","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMe1307415","article-title":"Inhibition of leukocyte trafficking in inflammatory bowel disease","volume":"369","author":"Cominelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib116","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in\u00a0patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.mayocp.2017.04.010_bib117","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.04.010_bib118","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mayocp.2017.04.010_bib119","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3748\/wjg.v20.i1.78","article-title":"Surgery for luminal Crohn's disease","volume":"20","author":"Yamamoto","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","article-title":"3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn's disease 2016, part 2: surgical management and special situations","volume":"11","author":"Gionchetti","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib121","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/MIB.0000000000000377","article-title":"Guidelines for medical treatment of Crohn's perianal fistulas: critical evaluation of therapeutic trials","volume":"21","author":"Schwartz","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2017.04.010_bib122","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.gastro.2016.10.039","article-title":"American Gastroenterological Association technical review on the management of Crohn's disease after surgical resection","volume":"152","author":"Regueiro","year":"2017","journal-title":"Gastroenterology"},{"issue":"9976","key":"10.1016\/j.mayocp.2017.04.010_bib123","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(14)61908-5","article-title":"Crohn's disease management after intestinal resection: a randomised trial","volume":"385","author":"De Cruz","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2017.04.010_bib124","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.cgh.2014.02.014","article-title":"Anti\u2013tumor necrosis factor therapy to prevent Crohn's disease recurrence after surgery","volume":"12","author":"Herfarth","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.04.010_bib125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib126","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2036.2012.05002.x","article-title":"Review article: the natural history of postoperative Crohn's disease recurrence","volume":"35","author":"Buisson","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib127","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.gastro.2009.12.037","article-title":"AGA medical position statement on the diagnosis and management of\u00a0colorectal neoplasia in inflammatory bowel disease","volume":"138","author":"Farraye","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.mayocp.2017.04.010_bib128","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1111\/j.1572-0241.2005.00287.x","article-title":"Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies","volume":"100","author":"Jess","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.04.010_bib129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2015.09.042","article-title":"Poor documentation of inflammatory bowel disease quality measures in academic, community, and private practice","volume":"14","author":"Feuerstein","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.MIB.0000437737.68841.87","article-title":"Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement","volume":"20","author":"Wasan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.mayocp.2017.04.010_bib131","first-page":"33","article-title":"Vaccination considerations for patients with inflammatory bowel disease","author":"Boroujerdi-Rad","year":"2011","journal-title":"Pract Gastroenterol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.04.010_bib132","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/ibd.21667","article-title":"Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge","volume":"17","author":"Wasan","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2017.04.010_bib133","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ajg.2009.733","article-title":"A\u00a0practical guide to vaccinating the inflammatory bowel disease patient","volume":"105","author":"Wasan","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib134","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2017.04.010_bib135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617303130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617303130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T22:21:17Z","timestamp":1535754077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617303130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":135,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0025619617303130"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.04.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crohn Disease: Epidemiology, Diagnosis, and Management","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}